Breaking News, Collaborations & Alliances

Zydus, XOMA Enter IO Agreement

To advance an IL-2-based immuno-oncology drug candidate that combines Zydus’ IL-2 with XOMA’s novel anti-IL-2 monoclonal antibody.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Zydus Cadila, a global pharmaceutical company, and XOMA Corp. have entered into a licensing agreement to advance an IL-2-based immuno-oncology (IO) drug candidate that combines Zydus’ IL-2 with XOMA’s novel anti-IL-2 monoclonal antibody. Zydus will advance the new IO candidate through clinical trials. Zydus has been granted exclusive rights to develop and commercialize the therapy in India, Brazil, Mexico and other emerging markets, and XOMA has the potential to receive royalties on sales in ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters